Ablynx: FY 2015 Results (Ablynx) - Feb 27, 2016 - Anticipated top-line data from P2b combination trial (NCT02309359) in rheumatoid arthritis in H2 2016; Anticipated top-line data from P2b monotherapy trial (NCT02287922) in rheumatoid arthritis in H2 2016; Anticipated top-line data from P2 open label extension study (NCT02518620) in rheumatoid arthritis in H2 2018; Anticipated initiation of P3 trial in rheumatoid arthritis in H2 2017
Anticipated new P3 trial • Anticipated P2 data • Anticipated P2b data • Immunology • Rheumatoid Arthritis
|